Results 121 to 130 of about 131,258 (265)

Variant‐Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs

open access: yesInternational Journal of Cancer, EarlyView.
Mutual exclusivity and co‐occurrence of oncogenic mutations reflect functional antagonism or dependence and may inform therapeutic strategies. However, most studies overlook variant‐level patterns. In this comprehensive, cross‐cohort analysis of BRAF, KRAS, and EGFR mutation subtypes, the most significant mutual exclusivity pairs overlapped with ...
Freya Vaeyens   +14 more
wiley   +1 more source

Breast Cancer Outcomes From Ductal Carcinoma In Situ: A Population‐Based Cohort Study

open access: yesInternational Journal of Cancer, EarlyView.
Women with ductal carcinoma in situ have an elevated risk of subsequent invasive breast cancer, but how this risk evolves over time is unclear. In this population‐based study of ethnically diverse women diagnosed between 2000 and 2022 in New Zealand, the risk of invasive ipsilateral breast cancer persisted beyond 5 years.
Qian Chen   +5 more
wiley   +1 more source

The 9th Edition of the UICC TNM Classification of Malignant Tumours: Updates and Rationale for Change

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT The standard for assessing and recording the extent of the tumour, a necessity for most malignancies, is the Tumour Node Metastases (TNM) classification. The Union for International Cancer Control (UICC) TNM committee has defined this since the early 1950s.
James D. Brierley   +8 more
wiley   +1 more source

Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late‐stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high‐grade precursors before clinical symptoms ...
Christine Worthington   +105 more
wiley   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

open access: yesInternational Journal of Cancer, EarlyView.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy